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Abstract
Objective: Recent studies have shown the relevance of the cerebral grey matter involvement in multiple sclerosis (MS). The
number of new cortical lesions (CLs), detected by specific MRI sequences, has the potential to become a new research
outcome in longitudinal MS studies. Aim of this study is to define the statistical model better describing the distribution of
new CLs developed over 12 and 24 months in patients with relapsing-remitting (RR) MS.
Methods: Four different models were tested (the Poisson, the Negative Binomial, the zero-inflated Poisson and the zero-
inflated Negative Binomial) on a group of 191 RRMS patients untreated or treated with 3 different disease modifying
therapies. Sample size for clinical trials based on this new outcome measure were estimated by a bootstrap resampling
technique.
Results: The zero-inflated Poisson model gave the best fit, according to the Akaike criterion to the observed distribution of
new CLs developed over 12 and 24 months both in each treatment group and in the whole RRMS patients group adjusting
for treatment effect.
Conclusions: The sample size calculations based on the zero-inflated Poisson model indicate that randomized clinical trials
using this new MRI marker as an outcome are feasible.
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Introduction
In patients with multiple sclerosis (MS), the number of brain
white matter (WM) lesions as detected by magnetic resonance
imaging (MRI) is widely used as a marker for assessing and
monitoring disease activity. The negative binomial (NB) distribu-
tion is known as the statistical model best fitting the number of
WM lesions [1,2]. Recent pathological studies have shown that
lesions are often located in the grey matter of MS brains, especially
in the cerebral cortex [3,4]. Cortical lesions (CLs) have been
detected in vivo by means of specific MR sequences in many
research studies [5,6]. These have clearly shown the clinical
relevance of CLs, suggesting that they could become soon a valid
outcome in MS studies, adding to MRI WM lesions in assessing
disease activity and response to therapy [5,6,7].
The increased clinical relevance of CLs makes it important to
know the statistical properties of the distribution of CLs across a
population of MS patients for future trial design. These might be
different from those of WM lesions and need to be assessed
separately. Recently, the cross-sectional distribution of CLs was
studied in a group of 44 relapsing remitting (RR) MS patients and
the best model fitting their distribution across subjects was the NB
model [8]. However, for the appropriate design of future
longitudinal studies and clinical trials, it would be relevant to
know the distribution of new CLs longitudinally developed by MS
patients over the follow up period. Thus, in this study we analysed
the best statistical model fitting the distribution of new MRI CLs
developed over 1 and 2 years by a group of RRMS patients who
were either untreated or treated with 3 different disease modifying
drugs. Using this dataset, we also estimated the sample size for
trials using MRI-derived CLs as the primary outcome.
Methods
Patients
The dataset comprised 191 RRMS patients, 50 who remained
all the 2 years of the follow up period with no treatment and 141
that were part of a clinical study, randomized to subcutaneous
(s.c.) interferon (IFN) beta-1a (44 mcg three times weekly, 46
patients), intramuscular (i.m.) IFN beta-1a (30 mcg weekly, 47
patients) or glatiramer acetate (GA; 20 mg daily, 48 patients). All
patients were evaluated by MRI at baseline, 12 and 24 months.
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criteria, patients’ clinical and MRI characteristics are reported
extensively elsewhere [9].
The study received approval from the Ethics Committee of the
University Hospital of Padua and informed written consent was
obtained from all subjects.
MRI
Images were acquired using a 1.5 T scanner (Achieva, Philips
Medical Systems, Best, The Netherlands) with 33 mT/m power
gradient and a 16-channel head coil. Details about MRI
acquisition procedures are reported previously [9]. Briefly, double
inversion recovery (DIR) acquisition parameters were the
following: repetition time (TR)=15631 ms; echo time
(TE)=25 ms; inversion time (TI)=3400 ms; delayJ=325 ms;
echo train length (ETL)=17; 50 contiguous axial slices with
thickness=3 mm; matrix sizeJ=1306256; and field of view
(FOV)=2506200 mm
2.
Imaging was carried out at the imaging centre of the University
of Padua, Italy, and all images were assessed by the consensus of
two experienced observers (MC and PG) who were blinded to the
patients’ identity and treatment. The number of new CLs was
counted on the 12 and 24 month scans as compared to the
baseline scan.
Statistical analysis
Four models were fitted to the distribution of the number of new
CLs counted over 12 and 24 months: the basic Poisson and the
basic NB model, the zero-inflated Poisson (ZIP) and the zero-
inflated NB (ZINB). The Poisson and the NB models are well
known and were extensively described previously [1,2]. Zero-
inflated distributions are interesting models that have the
capability of distinguishing between the so-called ‘‘structural
zeros’’ (i.e., zero counts that are somehow inevitable), and
sampling zeros, (i.e., zero counts occurring by chance) and thus
they are two-component mixture models combining a proper
probability distribution for counts with a portion of extra-counts
located on zero. Testing zero-inflated models was motivated by the
fact that CLs are expected to be less numerous than WM lesions,
so more zeros are expected in their distribution. The 4 models
were evaluated separately and on the whole dataset adjusting for
treatment arm. Goodness of fit of different models was evaluated
by the log-likelihood and the Akaike Information Criterion (AIC)
and compared by the likelihood ratio (LR) test for nested models
and the Vuong test for non-nested models. Model parameters were
estimated using R (http://www.R-project.org).
Sample size for active controlled trials using the number of new
CLs over 1 and 2 years as the primary outcome was estimated.
The control arm was assumed to be made up of patients treated
with s.c. IFN beta-1a or i.m. IFN beta-1a or GA. Sample size was
estimated resampling from the distribution that gave the best fit to
count data in each treatment group and assuming different benefit
(ranging between a 30% and 50% lesion reduction) of the new
drug compared to the active control (power=90% and signifi-
cance level=5%).
Results
The descriptive statistics of the number of new CL counts over 1
and 2 years in the 3 treatment arms is reported elsewhere [9]. The
distributions of new CL counts over 1 and 2 years for each
Figure 1. Histograms of the observed and predicted distribution of CLs over 1 and 2 years. Histograms of the distribution of the number
of cortical lesions counted over 1 and 2 years in the non-treated and in the 3 treated groups, and their probability distribution implied by the Poisson
(blue lines), the zero-inflated Poisson (yellow lines), the Negative Binomial (red lines) and the zero-inflated Negative Binomial (green lines) models.
The Akaike Information Criterion (AIC) is calculated on the whole group of patients adjusting for treatment arm. Lower values of the AIC indicate
better fits.
doi:10.1371/journal.pone.0026712.g001
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models.
Frequency (%)
1 year Number of CLs Observed Poisson ZIP NB ZINB
No therapy 0 27.5 21.7 27.6 21.7 27.6
1 13.7 33.1 27.0 33.1 27.0
2 41.2 25.3 23.3 25.3 23.3
3 13.7 12.9 13.5 12.9 13.5
4 3.9 4.9 5.8 4.9 5.8
s.c. IFN beta-1a 0 73.9 69.1 73.7 74.5 73.7
1 17.4 25.6 17.7 18.3 17.7
2 6.5 4.7 6.6 4.7 6.6
3 2.2 0.6 1.7 1.5 1.7
i.m. IFN beta-1a 0 38.0 32.0 37.9 34.4 34.0
1 28.0 36.5 28.8 35.7 30.9
2 20.0 20.8 20.0 18.3 22.2
3 10.0 7.9 9.2 7.7 8.7
4 4.0 2.3 3.1 3.0 3.1
GA
0 45.8 45.3 46.1 45.3 46.1
1 33.3 36.2 33.8 35.3 35.0
2 16.7 14.2 15.0 14.2 14.2
3 4.2 3.8 3.8 3.8 3.8
Frequency (%)
2 years Number of CLs Observed Poisson ZIP NB ZINB
No therapy 0 17.6 5.2 21.3 10.1 21.3
1 11.8 15.3 12.6 20.4 12.6
2 15.7 22.7 18.6 21 18.6
3 9.8 22.4 18.4 16.4 18.4
4 19.6 16.6 13.6 12.9 13.6
5 13.7 9.8 8.0 7.6 8.0
6 7.8 4.8 4.0 4.3 4.0
7 2.0 2.0 1.7 2.5 1.7
8 2.0 0.8 0.6 2 0.6
s.c. IFN beta-1a 0 47.8 48.7 49.2 48.6 46.7
1 39.1 35.0 35.0 33.1 34.0
2 8.7 12.6 12.6 12.6 14.4
3 2.2 3.0 3.0 4.6 3.8
4 2.2 0.5 0.5 1.0 1.0
i.m. IFN beta-1a 0 28.0 20.2 28.0 26.4 29.5
1 26.0 32.3 24.4 29.8 22.8
2 20.0 25.8 22.9 21.2 21.8
3 18.0 13.8 14.3 11.9 13.7
4 0.0 5.5 6.7 6.2 7.9
5 8.0 1.8 2.5 2.7 2.9
GA 0 33.3 27.3 33.1 32.2 33.1
1 27.1 35.5 28.7 33.0 28.7
2 20.8 23.0 21.6 21.0 21.6
3 16.7 9.9 10.9 9.2 10.9
4 0.0 3.2 4.1 3.0 4.1
5 2.1 0.8 1.2 1.1 1.2
doi:10.1371/journal.pone.0026712.t001
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fitting is equivalent in some cases, with a better fit for the zero-
inflated models (yellow line=ZIP, green line=ZINB) as compared
to the simple Poisson and NB models (blue and red lines
respectively), especially for 2-year data. Fitting the 4 distributions
to the whole set of data adjusting for treatment arm indicates that
the ZIP model (AIC=487.3 over 1 and AIC=625.8 over 2 years)
gives the best fit to new CLs distribution. The AIC for 1 and 2
years were 489.1 and 641.8 for the Poisson model, 491.1 and
625.5 for the NB model and 489.3 and 627.8 for the ZINB model.
The formal models evaluation and the parameters of the
regression analysis are reported in Table 1 and 2. In Table 1
the frequencies of new MRI CLs over 1 and 2 years observed and
predicted under the Poisson, the NB, the ZIP and the ZINB
models are reported. A regression model based on these 4
distributions and adjusting for treatment arm was applied to the
full dataset. The beta coefficients and their standard errors (SE)
estimated by the regression models are reported in Table 2. For
the zero-inflated models the extra-zeros parameter was not
significantly different between treatment arms (both for 1 and
for 2 years of follow up) and therefore a common parameter was
estimated (% of extra-zeros in Table 2). The AIC criterion
indicates the best fit adjusting for the number of parameters used
by each model. Both for 1 and 2 years data, the best fit is given by
the ZIP model.
Sample sizes for active controlled trials using the number of new
CLs detected over 1 and 2 years were therefore estimated assuming a
ZIP distribution for lesion counts (Table 3). Sample sizes, calculated
foranactivecontrolledtrialwiths.c.IFNbeta-1a,i.m.IFNbeta-1aor
GA as comparator, a power of 90% and a significance level of 5%,
assuming a treatment effect of 50% ranged from 72 to 200 patients
per arm for a 1 year trial and from 48 to 110 for a 2-year trial. If the
minimum detectable treatment effect is assumed to be 30%, the
sample size needed ranged from 212 to 630 patients per arm for a 1
year trial and from 150 to 320 for a 2-year trial.
Discussion
The number of new MRI CLs detected on yearly scans of
RRMS patients under different treatment conditions is distributed
according to a skewed distribution typical of counts. The ZIP
model gave the best fit to the data.
The ZIP model is made by a mixture of the simple Poisson
model, whose parameter has a very straightforward interpretation
Table 2. Coefficients of the regression models on the whole dataset.
Poisson Negative Binomial Zero-inflated Poisson
Zero-inflated Negative
Binomial
1 year Intercept 0.43 (0.11) 0.56 (0.13) 0.56 (0.13)
Treatment arm
No therapy ref ref ref Ref
s.c. IFN beta-1a 21.42 (0.27) 21.42 (0.27) 21.41 (0.28) 21.41 (0.28)
i.m. IFN beta-1a 20.25 (0.18) 20.25 (0.18) 20.24 (0.19) 20.24 (0.19)
GA 20.66 (0.20) 20.66 (0.20) 20.66 (0.21) 20.66 (0.21)
Overdispersion (1/q) 2 0.00005 2 0.00004
% of extra-zeros 2213% 13%
Log-likelihood 2240.5 2240.5 2238.7 2238.7
AIC 489.1 491.1 487.3 489.3
Poisson vs Negative Binomial, p=0.98
Poisson vs Zero-inflated Poisson, p=0.15
Negative Binomial vs Zero-inflated Poisson=0.14
Negative Binomial vs Zero-inflated Negative Binomial, p=0.15
2 years Intercept 1.09 (0.08) 1.09 (0.10) 1.25 (0.09) 1.25 (0.09)
Treatment arm
No therapy ref ref ref ref
s.c. IFN beta-1a 21.42 (0.19) 21.42 (0.21) 21.44 (0.20) 21.44 (0.20)
i.m. IFN beta-1a 20.58 (0.14) 20.58 (0.17) 20.58 (0.15) 20.58 (0.15)
GA 20.83 (0.15) 20.83 (0.18) 20.84 (0.16) 20.84 (0.16)
Overdispersion (1/q) - 0.21 - 0.00006
% of extra-zeros - - 15% 15%
Log-likelihood 2316.9 2312.4 2307.9 2307.9
AIC 641.8 634.9 625.8 627.8
Poisson vs Negative Binomial, p=0.002
Poisson vs Zero-inflated Poisson, p=0.025
Negative Binomial vs Zero-inflated Poisson=0.05
Negative Binomial vs Zero-inflated Negative Binomial, p=0.05
doi:10.1371/journal.pone.0026712.t002
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account for overdispersion. These extra-zeros, namely excess of
subjects with zero new CLs, can be interpreted as a quote of
patients with ‘‘structural’’ zeros, that is, subjects who have zero
CLs not by chance, but because, for some reason, they do not
develop this kind of lesions. Thus, when used in the presence of a
treatment reducing the number of new CLs, the ZIP model is able
to discriminate if the new treatment has an effect in reducing the
mean value of lesions or in increasing the proportion of patients
with zero lesions, or both. This is an interesting issue to address
that would allow to better understanding the mechanism of action
of a new drug.
Since the ZIP model depends on 2 parameters (the mean value
and the extra-zeros), this is more convenient than the ZINB
model, which gave in the present study a data fitting as good as the
ZIP model, but after an estimation of 3 parameters (mean value,
overdispersion and extra-zeros).
It is worth to stress here some limitations of the study. First, in
the present analysis CLs were detected on images acquired at
1.5 T, which might not be the best approach to assess CLs (i.e.
higher fields might be better to evaluate this type of lesions).
However, MR scanners at 1.5 T field strength are still the most
widely used in clinics and are those that will most likely be used for
large clinical trials in the near future. Second, new CLs are not yet
considered as a relevant surrogate marker of disease in MS.
However, since the development of new agents acting on
neuroprotection and repair is a hot topic in the MS research,
there is the consequent need of new MRI outcomes for testing
these drugs in phase II studies. Among others, CLs are a promising
MRI outcome for neuroprotection and repair [10] and the present
analysis gives the technical basis for using them in future phase II
studies. Finally, since CLs are less frequent than WM lesions, the
sample size needed for a clinical trial is presumed to be very large,
making the trial unfeasible. In this study, by fitting the optimal ZIP
model to the distribution of the number of new CLs, we estimated
the sample size for clinical trials based on the number of new CLs
as the primary outcome and found that randomized clinical trials
using this new MRI marker as an outcome are feasible and can be
easily pursued.
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40% 80 100 170
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